About FJScience
Senior strategic expertise in oncology — built for partnership.
FJScience is a specialist strategic and medical advisory practice in oncology, founded to bring deep clinical and strategic expertise into the teams shaping how oncology assets are developed, positioned, and launched.
It was conceived based on a clear conviction: that the most consequential decisions in oncology development and commercialisation need specialist judgement that closes the gap between trial results and how cancer is actually treated.
Founder
Francisco Sapunar, MD.
A medical oncologist by training and a strategic medical advisor by practice — with twenty-six years of senior leadership across drug development, medical affairs, and product launches in oncology.
My career has been shaped by direct involvement in some of the most consequential developments in breast cancer treatment over the past twenty-six years — running the ATAC trial at the pivotal moment of the tamoxifen-to-aromatase inhibitor transition, working through the development of fulvestrant and lapatinib, the CDK4/6 inhibitor revolution, and most recently the launch of imlunestrant. Alongside breast cancer, my product launch experience extends across renal cell carcinoma (pazopanib), ovarian cancer (olaparib), as well as lung cancer (pembrolizumab).
What I bring to FJScience clients and partners is the combination this experience builds: clinical fluency anchored in continued connection to practising oncologists and key opinion leaders, strategic judgement shaped by senior responsibility across multiple paradigm shifts, and the rigour to be fair and objective with the data presented and a clear view of the broader landscape. Each client and partner works directly with senior strategic expertise.
Francisco Sapunar, MD
The company
FJScience Ltd.
FJScience Consultancy Limited is a UK private limited company, registered in London under company number 12573226. The practice is positioned to serve clients and partners globally.
Get in touch.
Whether you're in a medical education organisation considering a partnership, a pharma company exploring engagement, or a peer looking to discuss the field — we'd love to hear from you.